Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

May 2021

Diadem presents new data showing its blood-based biomarker test accurately predicts progression to Alzheimer’s disease 7 years before symptoms occur

Diadem, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD) and headquartered in Milan within OpenZone campus, last week announced new data showing that its AlzoSure® prognostic biomarker test can accurately predict progression to Alzheimer’s disease six to seven years before symptoms appear.

The new study results were presented at the 2021 Alzheimer's Association International Conference® (AAIC) Satellite Symposium and during the 2021 BioEquity Europe.

This new report is based on health data collected from 224 participants in the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging (AIBL). The well-characterized cohort includes extensive longitudinal patient data and plasma samples.

The prognostic performance of Diadem’s biomarker test in predicting progression to Alzheimer’s dementia was high, with “area under the curve” values (a measure of the accuracy of a quantitative diagnostic test) above 0.90 for both preclinical pre-symptomatic patients and for prodromal stage patients beginning to manifest early dementia symptoms.

The study results

The study results indicated promising positive and negative predictive values of about 90% when predicting the progression to AD dementia more than 6 years prior to symptom onset.

The Diadem biomarker test also achieved high diagnostic performance in the ability to differentiate cognitively normal individuals from patients with AD dementia.

Paul Kinnon
Diadem’s CEO


This is good news for the millions of families worldwide who will confront AD in the coming years, since our simple, accessible blood-based assay will allow for therapeutic interventions early in the disease process, when slowing or stopping disease progression is far more feasible. It will also enable more effective clinical trials of investigative therapies for AD. We look forward to sharing the full results from the Clinical Validation study in the coming months.


Simona Piccirella
PhD, Diadem’s Vice President of Product Development and Operations

Our simple, affordable and accessible blood-based technology will enable individuals to be widely screened in primary care settings, setting the stage for achieving tangible progress against this devastating disease that could benefit millions of people worldwide.